Literature DB >> 20738200

ECG detection of murine chagasic cardiomyopathy.

Christopher S Eickhoff1, Cade T Lawrence, John E Sagartz, Leesa A Bryant, Arthur J Labovitz, Simil S Gala, Daniel F Hoft.   

Abstract

Chagas' disease, induced by Trypanosoma cruzi , is a common cause of infectious myocarditis. Recent clinical treatment trials and vaccine studies indicate that chagasic immunopathology is directed against the parasite and not self-antigens. Therefore, vaccines may have the potential to protect against disease progression. Certain combinations of mouse and parasite strains produce significant histopathology and can be used for safety analyses of new vaccination strategies. The goals of this study were to determine (1) whether the development of chagasic cardiomyopathy in the murine model could be identified by electrocardiogram (ECG); and (2) whether these potential chagasic ECG changes would correlate with histopathologic findings. Groups of BALB/c, C57BL/6, and C3H mice were infected with different parasite strains (Tulahuén, Brazil, or Sylvio-X10/4) and evaluated weekly by ECG. Selected tissues from subsets of mice were harvested periodically for blinded histologic evaluation. Significantly increased proportions of BALB/c mice infected with Brazil and Tulahuén strain parasites displayed prolonged QT intervals. Prolonged mean QT intervals detected in infected BALB/c mice significantly correlated with chagasic histopathologic changes. These results indicate that ECG can be used as a non-invasive method to screen for immune-mediated damage resulting in chagasic cardiomyopathy in the murine model.

Entities:  

Mesh:

Year:  2010        PMID: 20738200      PMCID: PMC3150498          DOI: 10.1645/GE-2396.1

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  22 in total

1.  Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection.

Authors:  O K Giddings; C S Eickhoff; T J Smith; L A Bryant; D F Hoft
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

2.  Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives.

Authors:  M S Braga; L Lauria-Pires; E R Argañaraz; R J Nascimento; A R Teixeira
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2000 May-Jun       Impact factor: 1.846

3.  Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives.

Authors:  L Lauria-Pires; M S Braga; A C Vexenat; N Nitz; A Simões-Barbosa; D L Tinoco; A R Teixeira
Journal:  Am J Trop Med Hyg       Date:  2000 Sep-Oct       Impact factor: 2.345

4.  Blood donor screening for chagas disease--United States, 2006-2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-02-23       Impact factor: 17.586

5.  Long term evaluation of etiological treatment of chagas disease with benznidazole.

Authors:  J Romeu Cancado
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2002 Jan-Feb       Impact factor: 1.846

6.  Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.

Authors:  Daniel F Hoft; Christopher S Eickhoff; Olivia K Giddings; José R C Vasconcelos; Maurício M Rodrigues
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

7.  Electrocardiographic characteristics in a population with high rates of seropositivity for Trypanosoma cruzi infection.

Authors:  S Williams-Blangero; T Magalhaes; E Rainwater; J Blangero; R Corrêa-Oliveira; J L Vandeberg
Journal:  Am J Trop Med Hyg       Date:  2007-09       Impact factor: 2.345

8.  Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.

Authors:  Nisha Garg; Rick L Tarleton
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.

Authors:  Anita R Schnapp; Chris S Eickhoff; Donata Sizemore; Roy Curtiss; Daniel F Hoft
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

10.  Trypanosoma cruzi reinfections in mice determine the severity of cardiac damage.

Authors:  Juan M Bustamante; Héctor W Rivarola; Alicia R Fernández; Julio E Enders; Ricardo Fretes; José A Palma; Patricia A Paglini-Oliva
Journal:  Int J Parasitol       Date:  2002-06-15       Impact factor: 3.981

View more
  21 in total

1.  Advances in imaging of animal models of Chagas disease.

Authors:  Linda A Jelicks; Herbert B Tanowitz
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

2.  Mice with Genetic Deletion of Group VIA Phospholipase A2β Exhibit Impaired Macrophage Function and Increased Parasite Load in Trypanosoma cruzi-Induced Myocarditis.

Authors:  Janhavi Sharma; Jennifer R Blase; Daniel F Hoft; John O Marentette; John Turk; Jane McHowat
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

3.  Prolonged Tpeak-Tend interval in anti-Ro52 antibody-positive connective tissue diseases.

Authors:  Ayse Nur Tufan; Saim Sag; Mustafa Ferhat Oksuz; Selime Ermurat; Belkis Nihan Coskun; Mustafa Gullulu; Ferah Budak; Ibrahim Baran; Yavuz Pehlivan; Ediz Dalkilic
Journal:  Rheumatol Int       Date:  2016-05-18       Impact factor: 2.631

4.  CD8+ T-cells expressing interferon gamma or perforin play antagonistic roles in heart injury in experimental Trypanosoma cruzi-elicited cardiomyopathy.

Authors:  Jaline Coutinho Silverio; Isabela Resende Pereira; Márcio da Costa Cipitelli; Nathália Ferreira Vinagre; Maurício Martins Rodrigues; Ricardo Tostes Gazzinelli; Joseli Lannes-Vieira
Journal:  PLoS Pathog       Date:  2012-04-19       Impact factor: 6.823

5.  Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in Chagas disease.

Authors:  Fabiane L de Oliveira; Tania C Araújo-Jorge; Elen M de Souza; Gabriel M de Oliveira; Wim M Degrave; Jean-Jacques Feige; Sabine Bailly; Mariana C Waghabi
Journal:  PLoS Negl Trop Dis       Date:  2012-06-12

Review 6.  A new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imaging.

Authors:  Michael D Lewis; Amanda Fortes Francisco; Martin C Taylor; John M Kelly
Journal:  J Biomol Screen       Date:  2014-10-08

Review 7.  Translational challenges of animal models in Chagas disease drug development: a review.

Authors:  Eric Chatelain; Nandini Konar
Journal:  Drug Des Devel Ther       Date:  2015-08-19       Impact factor: 4.162

8.  MicroRNA Transcriptome Profiling in Heart of Trypanosoma cruzi-Infected Mice: Parasitological and Cardiological Outcomes.

Authors:  Isabela Cunha Navarro; Frederico Moraes Ferreira; Helder I Nakaya; Monique Andrade Baron; Gláucia Vilar-Pereira; Isabela Resende Pereira; Ana Maria Gonçalves Silva; Juliana Monte Real; Thales De Brito; Christophe Chevillard; Joseli Lannes-Vieira; Jorge Kalil; Edecio Cunha-Neto; Ludmila Rodrigues Pinto Ferreira
Journal:  PLoS Negl Trop Dis       Date:  2015-06-18

9.  Absence of calcium-independent phospholipase A2 β impairs platelet-activating factor production and inflammatory cell recruitment in Trypanosoma cruzi-infected endothelial cells.

Authors:  Janhavi Sharma; Christopher S Eickhoff; Daniel F Hoft; John O Marentette; John Turk; Jane McHowat
Journal:  Physiol Rep       Date:  2014-01-06

Review 10.  Long QT Syndrome: An Emerging Role for Inflammation and Immunity.

Authors:  Pietro Enea Lazzerini; Pier Leopoldo Capecchi; Franco Laghi-Pasini
Journal:  Front Cardiovasc Med       Date:  2015-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.